Methotrexate

Articles · Medicine Compliance Aid Stability · Lactation Safety Information ·

68887009

Articles

Safety in Lactation: Drugs which suppress the rheumatic disease process

Disease-modifying anti-rheumatic drugs (DMARDs) have a varied pharmacology, mainly either modifying the immune response to the disease or modifying the disease process. The choice of… Abatacept Adalimumab Anakinra Azathioprine Belimumab Certolizumab pegol Chloroquine Ciclosporin Etanercept Golimumab Hydroxychloroquine Infliximab Leflunomide Methotrexate Penicillamine Rituximab Sodium aurothiomalate Sulfasalazine Tocilizumab Ustekinumab

Medicine Compliance Aid Stability

Maxtrex · Pharmacia Ltd

Pharmacia Ltd
Maxtrex
Tablets 2.5mg, 10mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Tablets are hygroscopic and cytotoxic.
11th February 2015

generic · Amdipharm Mercury Co Ltd

Amdipharm Mercury Co Ltd
generic
Tablets 2.5mg, 10mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Tablets are hygroscopic and cytotoxic.
11th February 2015

generic · Hospira UK

Hospira UK
generic
Tablets 2.5mg, 10mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Tablets are hygroscopic and cytotoxic.
11th February 2015

generic · Orion Pharma (UK) Ltd

Orion Pharma (UK) Ltd
generic
Tablets 2.5mg, 10mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Tablets are hygroscopic and cytotoxic.
11th February 2015

generic · Sandoz Ltd

Sandoz Ltd
generic
Tablets 2.5mg, 10mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Tablets are hygroscopic and cytotoxic.
11th February 2015

Lactation Safety Information

As antineoplastic

As antineoplastic
Limited published evidence indicates small amounts in breast milk
If used as monotherapy, monitor infant’s blood count and do not resume breastfeeding until at least 4 days after a dose – longer with high doses
Discontinue breastfeeding if used in combination with other antineoplastics
17th September 2018

For rheumatoid arthritis

For rheumatoid arthritis
See summary
Limited published evidence indicates small amounts in breast milk after weekly administration
Monitor infant’s blood count and do not resume breastfeeding until at least 24 hours after a weekly dose not exceeding 25mg

For psoriasis

For psoriasis
Topical psoriasis preparation / corticosteroid if appropriate
Limited published evidence indicates small amounts in breast milk after weekly administration
Monitor infant’s blood count and do not resume breastfeeding until at least 24 hours after a weekly dose not exceeding 25mg
16th September 2019

For inflammatory bowel disease

For inflammatory bowel disease
See summary
Limited published evidence indicates small amounts in breast milk after weekly administration
Monitor infant’s blood count and do not resume breastfeeding until at least 24 hours after a weekly dose not exceeding 25mg
19th May 2016